OGN Stock Analysis: Buy, Sell, or Hold?
OGN - Organon & Co.
$13.40
0.02 (0.15%)
▲
5d:
+0.15%
30d:
+1.06%
90d:
+95.05%
HOLD
MODERATE Confidence
Analysis Updated: Jun 3, 2026 12:00 AM ET
Earnings: May 07, 2026
0d
Smart Money Accumulation
None View Scanner →
Strength: 7.4/10
Get Alerted When OGN Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
📊 HOLD: OGN trades at premium valuation expecting 16.2% growth. Hold existing positions but don't chase. Wait for better entry.
📊 HOLD: OGN trades at premium valuation expecting 16.2% growth. Hold existing positions but don't chase. Wait for better entry.
Long-Term Wealth Forecast (2031)
Based on Analyst Consensus Growth & Historical Valuation
0% (Stagnation)
50% (Hyper Growth)
EST. PRICE IN 2031
$10.82
Based on 5.2% avg growth
INTRINSIC VALUE TODAY
$6.72
Trading above historical range
How this is calculated: We use a Growth Decay Model: starting with analyst consensus growth (adjusted above) and gradually slowing it down to a long-term terminal rate (4%) by Year 5. This provides a more realistic valuation than assuming constant hyper-growth. We then apply a 2.3x Exit PE.
In-depth Analysis How we analyze
Valuation Analysis: OGN is currently trading at $13.40, which is considered slightly high relative to its 30-day fair value range of $13.29 to $13.42. From a valuation perspective, the stock is trading at a premium (Forward PE: 3.7) compared to its historical average (2.3). At these levels, the market is pricing in 16.2% annual earnings growth. This growth rate appears achievable given the company's track record, suggesting the valuation is rational.
Technical Outlook: Technically, OGN is in a strong uptrend. The price is currently testing key support at $13.34. A bounce from this level would confirm strength, while a break below could signal further downside.
Market Sentiment: The stock shows a mixed technical setup (40/100), with neutral trendline and momentum signals. However, the stock is trading significantly above the average Wall Street target of $11.25. The stock is fairly positioned - fine to hold existing positions or accumulate slowly on dips, but not an urgent buy.
Technical Outlook: Technically, OGN is in a strong uptrend. The price is currently testing key support at $13.34. A bounce from this level would confirm strength, while a break below could signal further downside.
Market Sentiment: The stock shows a mixed technical setup (40/100), with neutral trendline and momentum signals. However, the stock is trading significantly above the average Wall Street target of $11.25. The stock is fairly positioned - fine to hold existing positions or accumulate slowly on dips, but not an urgent buy.
Quick Decision Summary
Current Position
SLIGHTLY HIGH
Historical Trading Range
$13.29 -
$13.42
Company Quality Score
58/100
(HOLD)
Volume Confirmation
HIGH
Confidence Score
54.8%
Protect Your Profits
OGN is technically overbought (RSI 74). Consider hedging now to protect against a potential pullback while keeping your upside.
View Profit Protection PlanAll Signals
- NEUTRAL: Mixed technical signals (40/100)
- BULLISH: High volume confirmation
- BEARISH: Trading 16.0% above Wall St target ($11.25)
- NEUTRAL: Trading at premium valuation - market expects 16.2% growth which is achievable
Trading Range Analysis
30-Day Trading Range
$13.29 -
$13.42
Current vs Trading Range
SLIGHTLY HIGH
Support & Resistance Levels
Support Level
$13.34
Resistance Level
$13.48
Current Trend
Strong Uptrend
Technical data as of
Jun 3, 2026
Fundamental Context
Forward P/E (Next Year Est.)
3.66
Wall Street Target
$11.25
(-16.0%)
Revenue Growth (YoY)
-3.5%
Earnings Growth (YoY)
66.7%
Profit Margin
4.0%
Valuation Premium vs History
+16.2% premium
PE vs Historical
3.7 vs 2.3
STRETCHED
Market-Implied Price Targets
If current PE multiple persists
Implied Growth (YoY):
+16.2%
(market-implied from PE analysis)
1-Year Target
$15.57
(+16%)
2-Year Target
$18.09
(+35%)
3-Year Target
$21.02
(+57%)
3-Yr Target (if PE normalizes)
(PE: 4→2)
PE COMPRESSION
$13.21
(-1%)
Earnings growth offset by PE compression
3-Year Scenarios
Using analyst projected EPS growth
Bull:
(PE: 21.9, Growth: 6.3%)
$96.44
(+620%)
Base:
(SPY PE: 3.7, Growth: 6.3%)
$16.11
(+20%)
Bear:
(PE: 2.3, Growth: 6.3%)
$10.12
(-24%)
📈
Valuation based on Current Earnings
RECOVERY PLAY: Stock looks expensive now (14x PE), but valuation improves significantly next year (4x PE) as earnings recover.
Trailing PE: 14.39 | Current EPS (TTM): $0.93
Bull Case
$29.44
(+121%)
Analyst growth 100.0%, PE expands to 15.8
Base Case
$26.76
(+100%)
Market implied 100.0%, PE stable at 14.4
Bear Case
$9.10
(-32%)
Severe decline -20.0%, PE contracts to 12.2
These are projections based on PE multiples and EPS growth scenarios, not predictions. Actual results may vary significantly.
Share & Embed Analysis
Last updated: June 03, 2026 6:26 PM ET
Data refreshes hourly during market hours. Next update: 7:26 PM
Data refreshes hourly during market hours. Next update: 7:26 PM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is OGN showing a specific setup today?
Insider Activity (6 Months)
0
Buys
0
Sells
0
Net
NEUTRAL
Top Rated Drug Manufacturers - General Stocks
Top-rated stocks in Drug Manufacturers - General by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
LLY
Eli Lilly and Company |
STRONG BUY
29 analysts |
$1211 | 59 HOLD |
|
GILD
Gilead Sciences Inc |
BUY
30 analysts |
$158 | 57 HOLD |
|
ABBV
AbbVie Inc |
BUY
28 analysts |
$253 | 66 BUY |
|
AMGN
Amgen Inc |
HOLD
32 analysts |
$352 | 65 BUY |
|
BIIB
Biogen Inc |
HOLD
37 analysts |
$219 | 55 HOLD |
Advanced OGN Option Strategies
Professional options setups generated by AI based on today's OGN price and gamma walls.
